These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Huang E; Esrailian E; Spiegel BM Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657 [TBL] [Abstract][Full Text] [Related]
26. Gut flora and hepatic encephalopathy in patients with cirrhosis. Riordan SM; Williams R N Engl J Med; 2010 Mar; 362(12):1140-2. PubMed ID: 20335591 [No Abstract] [Full Text] [Related]
27. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Sharma BC; Sharma P; Agrawal A; Sarin SK Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587 [TBL] [Abstract][Full Text] [Related]
28. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Agrawal A; Sharma BC; Sharma P; Sarin SK Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579 [TBL] [Abstract][Full Text] [Related]
29. Durability of rifaximin response in hepatic encephalopathy. Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586 [TBL] [Abstract][Full Text] [Related]
30. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Haj M; Rockey DC Am J Gastroenterol; 2020 May; 115(5):723-728. PubMed ID: 31658104 [TBL] [Abstract][Full Text] [Related]
31. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328 [TBL] [Abstract][Full Text] [Related]
32. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Ziada DH; Soliman HH; El Yamany SA; Hamisa MF; Hasan AM Arab J Gastroenterol; 2013 Sep; 14(3):116-22. PubMed ID: 24206740 [TBL] [Abstract][Full Text] [Related]
33. Beyond Lactulose: Treatment Options for Hepatic Encephalopathy. Said VJ; Garcia-Trujillo E Gastroenterol Nurs; 2019; 42(3):277-285. PubMed ID: 31145253 [TBL] [Abstract][Full Text] [Related]
35. Pharmacotherapy of hepatic encephalopathy in cirrhosis. Romero-Gómez M Expert Opin Pharmacother; 2010 Jun; 11(8):1317-27. PubMed ID: 20384539 [TBL] [Abstract][Full Text] [Related]
36. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain. Congly SE; Leise MD Am J Gastroenterol; 2014 Apr; 109(4):598. PubMed ID: 24698864 [No Abstract] [Full Text] [Related]
37. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. Flamm SL Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824 [TBL] [Abstract][Full Text] [Related]
38. [Hepatic encephalopathy and liver transplantation]. Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880 [TBL] [Abstract][Full Text] [Related]
39. Minimal hepatic encephalopathy. Stewart CA; Smith GE Nat Clin Pract Gastroenterol Hepatol; 2007 Dec; 4(12):677-85. PubMed ID: 18043677 [TBL] [Abstract][Full Text] [Related]